{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:29:39Z","timestamp":1793928579702,"version":"4.8.0"},"reference-count":293,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41584-025-01323-9","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:43:41Z","timestamp":1763034221000},"page":"42-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-6799","authenticated-orcid":false,"given":"Martina","family":"Rauner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-2118","authenticated-orcid":false,"given":"Aline","family":"Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"S Alivernini","year":"2022","unstructured":"Alivernini, S., Firestein, G. S. & McInnes, I. B. The pathogenesis of rheumatoid arthritis. Immunity 55, 2255\u20132270 (2022).","journal-title":"Immunity"},{"key":"1323_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semcdb.2008.07.016","volume":"19","author":"NA Sims","year":"2008","unstructured":"Sims, N. A. & Gooi, J. H. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin. Cell Dev. Biol. 19, 444\u2013451 (2008).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1323_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jcb.240560312","volume":"56","author":"TJ Martin","year":"1994","unstructured":"Martin, T. J. & Ng, K. W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J. Cell. Biochem. 56, 357\u2013366 (1994).","journal-title":"J. Cell. Biochem."},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1359\/jbmr.090533","volume":"24","author":"G Schett","year":"2009","unstructured":"Schett, G. & Teitelbaum, S. L. Osteoclasts and arthritis. J. Bone Miner. Res. 24, 1142\u20131146 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cyto.2017.04.012","volume":"98","author":"EY Kim","year":"2017","unstructured":"Kim, E. Y. & Moudgil, K. D. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine 98, 87\u201396 (2017).","journal-title":"Cytokine"},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"116468","DOI":"10.1016\/j.bone.2022.116468","volume":"162","author":"D Andreev","year":"2022","unstructured":"Andreev, D., Kachler, K., Schett, G. & Bozec, A. Rheumatoid arthritis and osteoimmunology: The adverse impact of a deregulated immune system on bone metabolism. Bone 162, 116468 (2022).","journal-title":"Bone"},{"key":"1323_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s001090100226","volume":"79","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer, L. C. & Heufelder, A. E. Role of receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79, 243\u2013253 (2001).","journal-title":"J. Mol. Med."},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.bonr.2023.101664","volume":"19","author":"A Marques-Carvalho","year":"2023","unstructured":"Marques-Carvalho, A., Kim, H.-N. & Almeida, M. The role of reactive oxygen species in bone cell physiology and pathophysiology. Bone Rep. 19, 101664 (2023).","journal-title":"Bone Rep."},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41413-024-00374-0","volume":"12","author":"JC Bertels","year":"2024","unstructured":"Bertels, J. C., He, G. & Long, F. Metabolic reprogramming in skeletal cell differentiation. Bone Res. 12, 57 (2024).","journal-title":"Bone Res."},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-019-0178-8","volume":"19","author":"M Tsukasaki","year":"2019","unstructured":"Tsukasaki, M. & Takayanagi, H. Osteoimmunology: evolving concepts in bone\u2013immune interactions in health and disease. Nat. Rev. Immunol. 19, 626\u2013642 (2019). This article provides a comprehensive review that discusses concepts of osteoimmunology.","journal-title":"Nat. Rev. Immunol."},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330\u20131347.e13 (2021).","journal-title":"Cell"},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1126\/science.1105786","volume":"190","author":"DG Walker","year":"1975","unstructured":"Walker, D. G. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190, 784\u2013785 (1975).","journal-title":"Science"},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.180.4088.875","volume":"180","author":"DG Walker","year":"1973","unstructured":"Walker, D. G. Osteopetrosis cured by temporary parabiosis. Science 180, 875\u2013875 (1973). This article is one of the earliest studies to show that osteoclasts can develop by fusion of monocytic cells.","journal-title":"Science"},{"key":"1323_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41556-019-0437-8","volume":"22","author":"Y Yahara","year":"2020","unstructured":"Yahara, Y. et al. Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat. Cell Biol. 22, 49\u201359 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1323_CR15","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1210\/endo-126-5-2733","volume":"126","author":"N Kurihara","year":"1990","unstructured":"Kurihara, N., Chenu, C., Miller, M., Civin, C. & Roodman, G. D. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 126, 2733\u20132741 (1990).","journal-title":"Endocrinology"},{"key":"1323_CR16","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","volume":"87","author":"N Udagawa","year":"1990","unstructured":"Udagawa, N. et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl Acad. Sci. USA 87, 7260\u20137264 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","volume":"246","author":"K Matsuzaki","year":"1998","unstructured":"Matsuzaki, K. et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246, 199\u2013204 (1998).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41586-019-1105-7","volume":"568","author":"CE Jacome-Galarza","year":"2019","unstructured":"Jacome-Galarza, C. E. et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568, 541\u2013545 (2019).","journal-title":"Nature"},{"key":"1323_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.4049\/jimmunol.1900665","volume":"204","author":"S Novak","year":"2020","unstructured":"Novak, S. et al. Osteoclasts derive predominantly from bone marrow\u2013resident CX3CR1+ precursor cells in homeostasis, whereas circulating CX3CR1+ cells contribute to osteoclast development during fracture repair. J. Immunol. 204, 868\u2013878 (2020).","journal-title":"J. Immunol."},{"key":"1323_CR20","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2004-01-0041","volume":"104","author":"A Rivollier","year":"2004","unstructured":"Rivollier, A. et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104, 4029\u20134037 (2004).","journal-title":"Blood"},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1359\/jbmr.090829","volume":"25","author":"A Gallois","year":"2010","unstructured":"Gallois, A. et al. Genome-wide expression analyses establish dendritic cells as a new osteoclast precursor able to generate bone-resorbing cells more efficiently than monocytes. J. Bone Miner. Res. 25, 661\u2013672 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR22","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.4049\/jimmunol.177.5.3314","volume":"177","author":"M Alnaeeli","year":"2006","unstructured":"Alnaeeli, M., Penninger, J. M. & Teng, Y.-T. A. Immune interactions with CD4+ T Cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. J. Immunol. 177, 3314\u20133326 (2006).","journal-title":"J. Immunol."},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/ard-2022-223817","volume":"83","author":"A Puchner","year":"2024","unstructured":"Puchner, A. et al. Bona fide dendritic cells are pivotal precursors for osteoclasts. Ann. Rheum. Dis. 83, 518\u2013528 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1173","volume":"12","author":"YCG Liu","year":"2024","unstructured":"Liu, Y. C. G. & Teng, A. Y. Distinct cross talk of IL-17 & TGF-\u03b2 with the immature CD11c+TRAF6(\u2212\/\u2212)-null myeloid dendritic cell-derived osteoclast precursor (mDDOCp) may engage signaling toward an alternative pathway of osteoclastogenesis for arthritic bone loss in vivo. Immun. Inflamm. Dis. 12, e1173 (2024).","journal-title":"Immun. Inflamm. Dis."},{"key":"1323_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.4049\/jimmunol.0903560","volume":"185","author":"R Maitra","year":"2010","unstructured":"Maitra, R. et al. Dendritic cell-mediated in vivo bone resorption. J. Immunol. 185, 1485\u20131491 (2010).","journal-title":"J. Immunol."},{"key":"1323_CR26","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1182\/blood-2008-01-132787","volume":"112","author":"A Wakkach","year":"2008","unstructured":"Wakkach, A. et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 112, 5074\u20135083 (2008).","journal-title":"Blood"},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s42255-020-00318-y","volume":"2","author":"M Tsukasaki","year":"2020","unstructured":"Tsukasaki, M. et al. Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution. Nat. Metab. 2, 1382\u20131390 (2020).","journal-title":"Nat. Metab."},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bonekey.2013.215","volume":"3","author":"NA Sims","year":"2014","unstructured":"Sims, N. A. & Martin, T. J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 3, 481 (2014). This article provides a comprehensive review that summarizes cellular activities and signalling crosstalk in bone remodelling.","journal-title":"Bonekey Rep."},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1359\/JBMR.051007","volume":"21","author":"C Jacquin","year":"2009","unstructured":"Jacquin, C., Gran, D. E., Lee, S. K., Lorenzo, J. A. & Aguila, H. L. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Miner. Res. 21, 67\u201377 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41586-019-1471-1","volume":"572","author":"S Culemann","year":"2019","unstructured":"Culemann, S. et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature 572, 670\u2013675 (2019). This article is a landmark paper showing different macrophage populations in the healthy and inflamed joint.","journal-title":"Nature"},{"key":"1323_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41413-022-00206-z","volume":"10","author":"Y Meirow","year":"2022","unstructured":"Meirow, Y. et al. Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss. Bone Res. 10, 36 (2022).","journal-title":"Bone Res."},{"key":"1323_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00277-007-0332-4","volume":"86","author":"N Takeyama","year":"2007","unstructured":"Takeyama, N. et al. Selective expansion of the CD14+\/CD16bright subpopulation of circulating monocytes in patients with hemophagocytic syndrome. Ann. Hematol. 86, 787\u2013792 (2007).","journal-title":"Ann. Hematol."},{"key":"1323_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231\u20131234 (2011).","journal-title":"Nat. Med."},{"key":"1323_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"Y-Y Kong","year":"1999","unstructured":"Kong, Y.-Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304\u2013309 (1999). This article is the first to report that activated T cells can activate osteoclasts during inflammatory conditions.","journal-title":"Nature"},{"key":"1323_CR35","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ajpath.2015.07.017","volume":"185","author":"K-W Kim","year":"2015","unstructured":"Kim, K.-W., Kim, H.-R., Kim, B.-M., Cho, M.-L. & Lee, S.-H. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am. J. Pathol. 185, 3011\u20133024 (2015).","journal-title":"Am. J. Pathol."},{"key":"1323_CR36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","volume":"75","author":"L Danks","year":"2016","unstructured":"Danks, L. et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann. Rheum. Dis. 75, 1187 (2016). This article shows that fibroblast-like synoviocytes are important contributors to inflammatory bone loss by producing RANKL.","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889\u2013901 (2002).","journal-title":"Dev. Cell"},{"key":"1323_CR38","doi-asserted-by":"publisher","first-page":"10922","DOI":"10.3390\/ijms222010922","volume":"22","author":"N Kondo","year":"2021","unstructured":"Kondo, N., Kuroda, T. & Kobayashi, D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int. J. Mol. Sci. 22, 10922 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1323_CR39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature02444","volume":"428","author":"T Koga","year":"2004","unstructured":"Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758\u2013763 (2004).","journal-title":"Nature"},{"key":"1323_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.20011681","volume":"195","author":"N Kim","year":"2002","unstructured":"Kim, N., Takami, M., Rho, J., Josien, R. & Choi, Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195, 201\u2013209 (2002).","journal-title":"J. Exp. Med."},{"key":"1323_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","volume":"231","author":"T Negishi-Koga","year":"2009","unstructured":"Negishi-Koga, T. & Takayanagi, H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev. 231, 241\u2013256 (2009).","journal-title":"Immunol. Rev."},{"key":"1323_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10020-024-00788-w","volume":"30","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. Recent advances of NFATc1 in rheumatoid arthritis-related bone destruction: mechanisms and potential therapeutic targets. Mol. Med. 30, 20 (2024).","journal-title":"Mol. Med."},{"key":"1323_CR43","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.21037\/atm-21-4332","volume":"9","author":"T Yu","year":"2021","unstructured":"Yu, T. et al. Klotho upregulates the interaction between RANK and TRAF6 to facilitate RANKL-induced osteoclastogenesis via the NF-\u03baB signaling pathway. Ann. Transl. Med. 9, 1499 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1323_CR44","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/nm1197-1285","volume":"3","author":"V Iotsova","year":"1997","unstructured":"Iotsova, V. et al. Osteopetrosis in mice lacking NF-\u03baB1 and NF-\u03baB2. Nat. Med. 3, 1285\u20131289 (1997).","journal-title":"Nat. Med."},{"key":"1323_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/85837","volume":"27","author":"R D\u00f6ffinger","year":"2001","unstructured":"D\u00f6ffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-\u03baB signaling. Nat. Genet. 27, 277\u2013285 (2001).","journal-title":"Nat. Genet."},{"key":"1323_CR46","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.3390\/ijms19103004","volume":"19","author":"K Lee","year":"2018","unstructured":"Lee, K., Seo, I., Choi, M. H. & Jeong, D. Roles of mitogen-activated protein kinases in osteoclast biology. Int. J. Mol. Sci. 19, 3004 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1323_CR47","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1136\/ard.61.suppl_2.ii40","volume":"61","author":"EF Wagner","year":"2002","unstructured":"Wagner, E. F. Functions of AP1 (Fos\/Jun) in bone development. Ann. Rheum. Dis. 61, ii40 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR48","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20051150","volume":"202","author":"M Asagiri","year":"2005","unstructured":"Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261\u20131269 (2005).","journal-title":"J. Exp. Med."},{"key":"1323_CR49","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","volume":"64","author":"P Soriano","year":"1991","unstructured":"Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693\u2013702 (1991).","journal-title":"Cell"},{"key":"1323_CR50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S1097-2765(00)80232-4","volume":"4","author":"BR Wong","year":"1999","unstructured":"Wong, B. R. et al. TRANCE, a TNF family member, activates Akt\/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041\u20131049 (1999).","journal-title":"Mol. Cell"},{"key":"1323_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165\u2013176 (1998).","journal-title":"Cell"},{"key":"1323_CR52","doi-asserted-by":"publisher","first-page":"108052","DOI":"10.1016\/j.celrep.2020.108052","volume":"32","author":"KM Cawley","year":"2020","unstructured":"Cawley, K. M. et al. Local production of osteoprotegerin by osteoblasts suppresses bone resorption. Cell Rep. 32, 108052 (2020).","journal-title":"Cell Rep."},{"key":"1323_CR53","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","volume":"61","author":"TN Crotti","year":"2002","unstructured":"Crotti, T. N. et al. Receptor activator NF-\u03baB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 61, 1047 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR54","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/rheumatology\/kel045","volume":"45","author":"AR Pettit","year":"2006","unstructured":"Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R. & Gravallese, E. M. RANKL protein is expressed at the pannus\u2013bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45, 1068\u20131076 (2006).","journal-title":"Rheumatology"},{"key":"1323_CR55","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299\u20131309 (2008).","journal-title":"Arthritis Rheum."},{"key":"1323_CR56","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","volume":"159","author":"AR Pettit","year":"2001","unstructured":"Pettit, A. R. et al. TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689\u20131699 (2001).","journal-title":"Am. J. Pathol."},{"key":"1323_CR57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.10097","volume":"46","author":"K Redlich","year":"2002","unstructured":"Redlich, K. et al. Tumor necrosis factor \u03b1-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785\u2013792 (2002).","journal-title":"Arthritis Rheum."},{"key":"1323_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41413-023-00312-6","volume":"12","author":"MS Hansen","year":"2024","unstructured":"Hansen, M. S. et al. Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity. Bone Res. 12, 5 (2024).","journal-title":"Bone Res."},{"key":"1323_CR59","volume":"6","author":"Y Omata","year":"2022","unstructured":"Omata, Y. et al. Interspecies single cell RNA seq analysis reveals the novel trajectory of osteoclast differentiation and therapeutic targets. J. Bone Miner. Res. 6, e10631 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","volume":"15","author":"KT Steeve","year":"2004","unstructured":"Steeve, K. T., Marc, P., Sandrine, T., Dominique, H. & Yannick, F. IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15, 49\u201360 (2004).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1323_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14\u201320 (2014).","journal-title":"Immunity"},{"key":"1323_CR62","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","volume":"10","author":"A Marahleh","year":"2019","unstructured":"Marahleh, A. et al. TNF-\u03b1 directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front. Immunol. 10, 2925 (2019).","journal-title":"Front. Immunol."},{"key":"1323_CR63","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam, J. et al. TNF-\u03b1 induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Investig. 106, 1481\u20131488 (2000).","journal-title":"J. Clin. Investig."},{"key":"1323_CR64","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.38218","volume":"66","author":"K Yokota","year":"2014","unstructured":"Yokota, K. et al. Combination of tumor necrosis factor \u03b1 and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol. 66, 121\u2013129 (2014). This article shows that the pro-inflammatory cytokines, TNF and IL-6, can stimulate osteoclasts in vitro and in vivo.","journal-title":"Arthritis Rheumatol."},{"key":"1323_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei, S., Kitaura, H., Zhou, P., Ross, F. P. & Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Investig. 115, 282\u2013290 (2005).","journal-title":"J. Clin. Investig."},{"key":"1323_CR66","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.1073\/pnas.0610812104","volume":"104","author":"J Zwerina","year":"2007","unstructured":"Zwerina, J. et al. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl Acad. Sci. USA 104, 11742\u201311747 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1323_CR67","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/oxfordjournals.jbchem.a003071","volume":"131","author":"ZH Lee","year":"2002","unstructured":"Lee, Z. H. et al. IL-1\u03b1 stimulation of osteoclast survival through the PI 3-kinase\/Akt and ERK pathways. J. Biochem. 131, 161\u2013166 (2002).","journal-title":"J. Biochem."},{"key":"1323_CR68","doi-asserted-by":"publisher","first-page":"782382","DOI":"10.1155\/2015\/782382","volume":"2015","author":"P Ruscitti","year":"2015","unstructured":"Ruscitti, P. et al. The role of IL-1\u03b2 in the bone loss during rheumatic diseases. Mediat. Inflamm. 2015, 782382 (2015).","journal-title":"Mediat. Inflamm."},{"key":"1323_CR69","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.4049\/jimmunol.145.10.3297","volume":"145","author":"Y Ishimi","year":"1990","unstructured":"Ishimi, Y. et al. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145, 3297\u20133303 (1990).","journal-title":"J. Immunol."},{"key":"1323_CR70","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","volume":"22","author":"V Strand","year":"2020","unstructured":"Strand, V. et al. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. Arthritis Res. Ther. 22, 250 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.joca.2008.09.007","volume":"17","author":"C Sanchez","year":"2009","unstructured":"Sanchez, C., Gabay, O., Salvat, C., Henrotin, Y. E. & Berenbaum, F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthr. Cartil. 17, 473\u2013481 (2009).","journal-title":"Osteoarthr. Cartil."},{"key":"1323_CR72","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","volume":"12","author":"S Adam","year":"2020","unstructured":"Adam, S. et al. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci. Transl. Med. 12, eaay4447 (2020). This article highlights JAK signalling as a crucial pathway for inflammatory bone loss and proposes it as a novel therapeutic pathway.","journal-title":"Sci. Transl. Med."},{"key":"1323_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/ar66","volume":"2","author":"RA Ortmann","year":"1999","unstructured":"Ortmann, R. A., Cheng, T., Visconti, R., Frucht, D. M. & O\u2019Shea, J. J. Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res. Ther. 2, 16 (1999).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR74","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1172\/JCI10530","volume":"107","author":"Y Abu-Amer","year":"2001","unstructured":"Abu-Amer, Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-\u03baB. J. Clin. Investig. 107, 1375\u20131385 (2001).","journal-title":"J. Clin. Investig."},{"key":"1323_CR75","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M510160200","volume":"281","author":"P Palmqvist","year":"2006","unstructured":"Palmqvist, P. et al. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J. Biol. Chem. 281, 2414\u20132429 (2006).","journal-title":"J. Biol. Chem."},{"key":"1323_CR76","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1002\/jcb.23269","volume":"112","author":"J Cheng","year":"2011","unstructured":"Cheng, J. et al. Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis. J. Cell. Biochem. 112, 3385\u20133392 (2011).","journal-title":"J. Cell. Biochem."},{"key":"1323_CR77","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1073\/pnas.041493198","volume":"98","author":"AC Bendixen","year":"2001","unstructured":"Bendixen, A. C. et al. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor \u03b31. Proc. Natl Acad. Sci. USA 98, 2443\u20132448 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1323_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46237-2","volume":"13","author":"TE Scott","year":"2023","unstructured":"Scott, T. E. et al. IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages. Sci. Rep. 13, 19589 (2023).","journal-title":"Sci. Rep."},{"key":"1323_CR79","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1172\/JCI200421795","volume":"114","author":"H Hata","year":"2004","unstructured":"Hata, H. et al. Distinct contribution of IL-6, TNF-\u03b1, IL-1, and IL-10 to T cell\u2013mediated spontaneous autoimmune arthritis in mice. J. Clin. Investig. 114, 582\u2013588 (2004).","journal-title":"J. Clin. Investig."},{"key":"1323_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-8-4","volume":"8","author":"KE Evans","year":"2007","unstructured":"Evans, K. E. & Fox, S. W. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 8, 4 (2007).","journal-title":"BMC Cell Biol."},{"key":"1323_CR81","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/ar3736","volume":"14","author":"NA Carter","year":"2012","unstructured":"Carter, N. A., Rosser, E. C. & Mauri, C. Interleukin-10 produced by B cells is crucial for the suppression of Th17\/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14, R32 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02683-x","volume":"9","author":"X Meng","year":"2018","unstructured":"Meng, X. et al. Hypoxia-inducible factor-1\u03b1 is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat. Commun. 9, 251 (2018).","journal-title":"Nat. Commun."},{"key":"1323_CR83","doi-asserted-by":"publisher","first-page":"691081","DOI":"10.3389\/fimmu.2021.691081","volume":"12","author":"L Sapra","year":"2021","unstructured":"Sapra, L. et al. Regulatory B cells (Bregs) inhibit osteoclastogenesis and play a potential role in ameliorating ovariectomy-induced bone loss. Front. Immunol. 12, 691081 (2021).","journal-title":"Front. Immunol."},{"key":"1323_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.imlet.2018.12.003","volume":"206","author":"B Lee","year":"2019","unstructured":"Lee, B., Oh, Y., Jo, S., Kim, T.-H. & Ji, J. D. A dual role of TGF-\u03b2 in human osteoclast differentiation mediated by Smad1 versus Smad3 signaling. Immunol. Lett. 206, 33\u201340 (2019).","journal-title":"Immunol. Lett."},{"key":"1323_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31475-1","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia, Y. et al. TGF\u03b2 reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis. Nat. Commun. 13, 3920 (2022).","journal-title":"Nat. Commun."},{"key":"1323_CR86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12865-021-00409-9","volume":"22","author":"MS AlQranei","year":"2021","unstructured":"AlQranei, M. S., Senbanjo, L. T., Aljohani, H., Hamza, T. & Chellaiah, M. A. Lipopolysaccharide- TLR-4 axis regulates osteoclastogenesis independent of RANKL\/RANK signaling. BMC Immunol. 22, 23 (2021).","journal-title":"BMC Immunol."},{"key":"1323_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4773","author":"MM Weivoda","year":"2023","unstructured":"Weivoda, M. M. & Bradley, E. W. Macrophages and bone remodeling. J. Bone Min. Res. https:\/\/doi.org\/10.1002\/jbmr.4773 (2023).","journal-title":"J. Bone Min. Res."},{"key":"1323_CR88","doi-asserted-by":"publisher","first-page":"eadj1252","DOI":"10.1126\/sciadv.adj1252","volume":"10","author":"MM Hanlon","year":"2024","unstructured":"Hanlon, M. M. et al. Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset. Sci. Adv. 10, eadj1252 (2024).","journal-title":"Sci. Adv."},{"key":"1323_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93784-x","volume":"15","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. Synovial macrophages drive severe joint destruction in established rheumatoid arthritis. Sci. Rep. 15, 12111 (2025).","journal-title":"Sci. Rep."},{"key":"1323_CR90","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4049\/jimmunol.181.2.1232","volume":"181","author":"MK Chang","year":"2008","unstructured":"Chang, M. K. et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol. 181, 1232\u20131244 (2008).","journal-title":"J. Immunol."},{"key":"1323_CR91","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/jbmr.4413","volume":"36","author":"L Batoon","year":"2021","unstructured":"Batoon, L. et al. Osteal macrophages support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model. J. Bone Miner. Res. 36, 2214\u20132228 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR92","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1182\/blood.2025028310","volume":"146","author":"T Isojima","year":"2025","unstructured":"Isojima, T. et al. Bone marrow neutrophil progenitors suppress osteoclast formation in murine cortical and trabecular bone. Blood 146, 1331\u20131345 (2025).","journal-title":"Blood"},{"key":"1323_CR93","doi-asserted-by":"publisher","first-page":"eabd2688","DOI":"10.1126\/sciadv.abd2688","volume":"6","author":"LJ O\u2019Neil","year":"2020","unstructured":"O\u2019Neil, L. J. et al. Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Sci. Adv. 6, eabd2688 (2020).","journal-title":"Sci. Adv."},{"key":"1323_CR94","doi-asserted-by":"publisher","first-page":"117310","DOI":"10.1016\/j.bone.2024.117310","volume":"190","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Neutrophils inhibit bone formation by directly contacting osteoblasts and suppressing osteogenic differentiation. Bone 190, 117310 (2025).","journal-title":"Bone"},{"key":"1323_CR95","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","volume":"19","author":"A Herrero-Cervera","year":"2022","unstructured":"Herrero-Cervera, A., Soehnlein, O. & Kenne, E. Neutrophils in chronic inflammatory diseases. Cell. Mol. Immunol. 19, 177\u2013191 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"1323_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35801-z","volume":"14","author":"J Li","year":"2023","unstructured":"Li, J. et al. TGF\u03b21+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice. Nat. Commun. 14, 159 (2023).","journal-title":"Nat. Commun."},{"key":"1323_CR97","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nm.3547","volume":"20","author":"C Schauer","year":"2014","unstructured":"Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511\u2013517 (2014).","journal-title":"Nat. Med."},{"key":"1323_CR98","doi-asserted-by":"publisher","first-page":"149743","DOI":"10.1016\/j.bbrc.2024.149743","volume":"705","author":"K Numazaki","year":"2024","unstructured":"Numazaki, K. et al. Neutrophil extracellular traps inhibit osteoclastogenesis. Biochem. Biophys. Res. Commun. 705, 149743 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1323_CR99","doi-asserted-by":"publisher","first-page":"178ra40","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra40 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1323_CR100","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/jleuko\/qiae173","volume":"116","author":"PH Gazzinelli-Guimaraes","year":"2024","unstructured":"Gazzinelli-Guimaraes, P. H., Jones, S. M., Voehringer, D., Mayer-Barber, K. D. & Samarasinghe, A. E. Eosinophils as modulators of host defense during parasitic, fungal, bacterial, and viral infections. J. Leukoc. Biol. 116, 1301\u20131323 (2024).","journal-title":"J. Leukoc. Biol."},{"key":"1323_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45261-8","volume":"15","author":"D Andreev","year":"2024","unstructured":"Andreev, D. et al. Eosinophils preserve bone homeostasis by inhibiting excessive osteoclast formation and activity via eosinophil peroxidase. Nat. Commun. 15, 1067 (2024).","journal-title":"Nat. Commun."},{"key":"1323_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14092","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Osteoclasts and osteoarthritis: novel intervention targets and therapeutic potentials during aging. Aging Cell 23, e14092 (2024).","journal-title":"Aging Cell"},{"key":"1323_CR103","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/annrheumdis-2020-218902","volume":"80","author":"D Andreev","year":"2021","unstructured":"Andreev, D. et al. Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Ann. Rheum. Dis. 80, 451\u2013468 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11596","volume":"7","author":"Z Chen","year":"2016","unstructured":"Chen, Z. et al. Th2 and eosinophil responses suppress inflammatory arthritis. Nat. Commun. 7, 11596 (2016).","journal-title":"Nat. Commun."},{"key":"1323_CR105","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1182\/bloodadvances.2017008540","volume":"1","author":"Y Xiao","year":"2017","unstructured":"Xiao, Y. et al. Macrophages and osteoclasts stem from a bipotent progenitor downstream of a macrophage\/osteoclast\/dendritic cell progenitor. Blood Adv. 1, 1993\u20132006 (2017).","journal-title":"Blood Adv."},{"key":"1323_CR106","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00011-022-01608-9","volume":"71","author":"CW Ng","year":"2022","unstructured":"Ng, C. W. et al. Human mast cells induce osteoclastogenesis through cell surface RANKL. Inflamm. Res. 71, 1261\u20131270 (2022).","journal-title":"Inflamm. Res."},{"key":"1323_CR107","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1189\/jlb.0611308","volume":"91","author":"R Wang","year":"2011","unstructured":"Wang, R., Jaw, J. J., Stutzman, N. C., Zou, Z. & Sun, P. D. Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1. J. Leukoc. Biol. 91, 299\u2013309 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"1323_CR108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1089\/jir.2011.0019","volume":"32","author":"J Cheng","year":"2011","unstructured":"Cheng, J. et al. Molecular mechanisms of the biphasic effects of interferon-\u03b3 on osteoclastogenesis. J. Interf. Cytokine Res. 32, 34\u201345 (2011).","journal-title":"J. Interf. Cytokine Res."},{"key":"1323_CR109","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/imm.12449","volume":"145","author":"S Feng","year":"2015","unstructured":"Feng, S. et al. Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. Immunology 145, 367\u2013379 (2015).","journal-title":"Immunology"},{"key":"1323_CR110","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.4373","volume":"23","author":"S Rauber","year":"2017","unstructured":"Rauber, S. et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 23, 938\u2013944 (2017).","journal-title":"Nat. Med."},{"key":"1323_CR111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.celrep.2018.06.005","volume":"24","author":"Y Omata","year":"2018","unstructured":"Omata, Y. et al. Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice. Cell Rep. 24, 169\u2013180 (2018).","journal-title":"Cell Rep."},{"key":"1323_CR112","doi-asserted-by":"publisher","first-page":"115335","DOI":"10.1016\/j.bone.2020.115335","volume":"136","author":"Y Omata","year":"2020","unstructured":"Omata, Y. et al. Type 2 innate lymphoid cells inhibit the differentiation of osteoclasts and protect from ovariectomy-induced bone loss. Bone 136, 115335 (2020).","journal-title":"Bone"},{"key":"1323_CR113","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.immuni.2005.01.011","volume":"22","author":"MA Stark","year":"2005","unstructured":"Stark, M. A. et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285\u2013294 (2005).","journal-title":"Immunity"},{"key":"1323_CR114","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-019-1984-x","volume":"21","author":"A Takaki-Kuwahara","year":"2019","unstructured":"Takaki-Kuwahara, A. et al. CCR6+ group 3 innate lymphoid cells accumulate in inflamed joints in rheumatoid arthritis and produce Th17 cytokines. Arthritis Res. Ther. 21, 198 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR115","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-\u03b3. Nature 408, 600\u2013605 (2000).","journal-title":"Nature"},{"key":"1323_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141008","volume":"131","author":"A Levescot","year":"2021","unstructured":"Levescot, A. et al. IL-1\u03b2-driven osteoclastogenic T regulatory cells accelerate bone erosion in arthritis. J. Clin. Investig. 131, e141008 (2021).","journal-title":"J. Clin. Investig."},{"key":"1323_CR117","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.bor.0000231912.24740.a5","volume":"18","author":"K Sato","year":"2006","unstructured":"Sato, K. & Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419\u2013426 (2006).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1323_CR118","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Investig. 103, 1345\u20131352 (1999).","journal-title":"J. Clin. Investig."},{"key":"1323_CR119","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts, E. The IL-23\u2013IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 11, 415\u2013429 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1323_CR120","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/cdd.2009.74","volume":"16","author":"H Huang","year":"2009","unstructured":"Huang, H. et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ. 16, 1332\u20131343 (2009).","journal-title":"Cell Death Differ."},{"key":"1323_CR121","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/eji.201141871","volume":"42","author":"K Zwerina","year":"2012","unstructured":"Zwerina, K. et al. Anti IL-17A therapy inhibits bone loss in TNF-\u03b1-mediated murine arthritis by modulation of the T-cell balance. Eur. J. Immunol. 42, 413\u2013423 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1323_CR122","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/jbmr.2868","volume":"31","author":"L Ib\u00e1\u00f1ez","year":"2016","unstructured":"Ib\u00e1\u00f1ez, L. et al. Inflammatory osteoclasts prime TNF\u03b1-producing CD4+ T cells and express CX3CR1. J. Bone Miner. Res. 31, 1899\u20131908 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR123","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","volume":"108","author":"X Valencia","year":"2006","unstructured":"Valencia, X. et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108, 253\u2013261 (2006).","journal-title":"Blood"},{"key":"1323_CR124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11914-017-0356-1","volume":"15","author":"A Bozec","year":"2017","unstructured":"Bozec, A. & Zaiss, M. M. T regulatory cells in bone remodelling. Curr. Osteoporos. Rep. 15, 121\u2013125 (2017).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1323_CR125","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/art.23138","volume":"56","author":"MM Zaiss","year":"2007","unstructured":"Zaiss, M. M. et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 56, 4104\u20134112 (2007).","journal-title":"Arthritis Rheum."},{"key":"1323_CR126","doi-asserted-by":"publisher","first-page":"235ra60","DOI":"10.1126\/scitranslmed.3007764","volume":"6","author":"A Bozec","year":"2014","unstructured":"Bozec, A. et al. T cell costimulation molecules CD80\/86 inhibit osteoclast differentiation by inducing the IDO\/tryptophan pathway. Sci. Transl. Med. 6, 235ra60 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1323_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038199","volume":"7","author":"ZS Buchwald","year":"2012","unstructured":"Buchwald, Z. S., Kiesel, J. R., DiPaolo, R., Pagadala, M. S. & Aurora, R. Osteoclast activated FoxP3+CD8+ T-cells suppress bone resorption in vitro. PLoS One 7, e38199 (2012).","journal-title":"PLoS One"},{"key":"1323_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76038-w","volume":"10","author":"C Alvarez","year":"2020","unstructured":"Alvarez, C. et al. Regulatory T cell phenotype and anti-osteoclastogenic function in experimental periodontitis. Sci. Rep. 10, 19018 (2020).","journal-title":"Sci. Rep."},{"key":"1323_CR129","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.berh.2017.09.015","volume":"31","author":"G Schett","year":"2017","unstructured":"Schett, G. The role of ACPAs in at-risk individuals: early targeting of the bone and joints. Best Pract. Res. Clin. Rheumatol. 31, 53\u201358 (2017).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1323_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001228","volume":"7","author":"A Catrina","year":"2021","unstructured":"Catrina, A., Krishnamurthy, A. & Rethi, B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open 7, e001228 (2021).","journal-title":"RMD Open"},{"key":"1323_CR131","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Investig. 122, 1791\u20131802 (2012). This article describes the ability of auto-antibodies to modulate osteoclastogenesis.","journal-title":"J. Clin. Investig."},{"key":"1323_CR132","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2018-214967","volume":"78","author":"M Sun","year":"2019","unstructured":"Sun, M. et al. Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. Ann. Rheum. Dis. 78, 1621\u20131631 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR133","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1136\/annrheumdis-2013-204543","volume":"74","author":"L Laurent","year":"2015","unstructured":"Laurent, L. et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann. Rheum. Dis. 74, 1425 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR134","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1073\/pnas.1301001110","volume":"110","author":"M Seeling","year":"2013","unstructured":"Seeling, M. et al. Inflammatory monocytes and Fc\u03b3 receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc. Natl Acad. Sci. USA 110, 10729\u201310734 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1323_CR135","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.immuni.2023.02.019","volume":"56","author":"M Seeling","year":"2023","unstructured":"Seeling, M. et al. Immunoglobulin G-dependent inhibition of inflammatory bone remodeling requires pattern recognition receptor Dectin-1. Immunity 56, 1046\u20131063.e7 (2023).","journal-title":"Immunity"},{"key":"1323_CR136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13075-016-0957-6","volume":"18","author":"Y Ota","year":"2016","unstructured":"Ota, Y. et al. Generation mechanism of RANKL+ effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 18, 67 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR137","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/art.39489","volume":"68","author":"N Meednu","year":"2016","unstructured":"Meednu, N. et al. Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis. Arthritis Rheumatol. 68, 805\u2013816 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1323_CR138","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-022-00189-x","volume":"10","author":"X Meng","year":"2022","unstructured":"Meng, X. et al. Estrogen-mediated downregulation of HIF-1\u03b1 signaling in B lymphocytes influences postmenopausal bone loss. Bone Res. 10, 15 (2022).","journal-title":"Bone Res."},{"key":"1323_CR139","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1136\/ard.2011.153312","volume":"70","author":"L Yeo","year":"2011","unstructured":"Yeo, L. et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann. Rheum. Dis. 70, 2022 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143060","volume":"131","author":"N Komatsu","year":"2021","unstructured":"Komatsu, N. et al. Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J. Clin. Investig. 131, e143060 (2021).","journal-title":"J. Clin. Investig."},{"key":"1323_CR141","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/annrheumdis-2013-204116","volume":"74","author":"L Yeo","year":"2015","unstructured":"Yeo, L. et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann. Rheum. Dis. 74, 928 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR142","first-page":"8","volume":"6","author":"Y Li","year":"2014","unstructured":"Li, Y., Terauchi, M., Vikulina, T., Roser-Page, S. & Weitzmann, M. N. B cell production of both OPG and RANKL is significantly increased in aged mice. Open Bone J. 6, 8\u201317 (2014).","journal-title":"Open Bone J."},{"key":"1323_CR143","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246\u2013251 (2019). This article refines the fibroblast subsets that support inflammation-induced osteoclastogenesis in arthritis.","journal-title":"Nature"},{"key":"1323_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02892-y","volume":"9","author":"F Mizoguchi","year":"2018","unstructured":"Mizoguchi, F. et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat. Commun. 9, 789 (2018).","journal-title":"Nat. Commun."},{"key":"1323_CR145","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019). This article provides a comprehensive analysis of cell types in the inflamed joint describing, for example, that IL-6 is mainly produced by synovial fibroblasts and IL-1 by monocytes.","journal-title":"Nat. Immunol."},{"key":"1323_CR146","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.20052187","volume":"203","author":"S Sawa","year":"2006","unstructured":"Sawa, S. et al. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3\/IL-7\u2013dependent homeostatic proliferation of CD4+ T cells. J. Exp. Med. 203, 1459\u20131470 (2006).","journal-title":"J. Exp. Med."},{"key":"1323_CR147","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu, N. & Takayanagi, H. Mechanisms of joint destruction in rheumatoid arthritis \u2014 immune cell\u2013fibroblast\u2013bone interactions. Nat. Rev. Rheumatol. 18, 415\u2013429 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1323_CR148","doi-asserted-by":"publisher","first-page":"939265","DOI":"10.3389\/fimmu.2022.939265","volume":"13","author":"Z Liang","year":"2022","unstructured":"Liang, Z. et al. Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3. Front. Immunol. 13, 939265 (2022).","journal-title":"Front. Immunol."},{"key":"1323_CR149","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejphar.2004.12.014","volume":"508","author":"T Ishikawa","year":"2005","unstructured":"Ishikawa, T. et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. Eur. J. Pharmacol. 508, 239\u2013247 (2005).","journal-title":"Eur. J. Pharmacol."},{"key":"1323_CR150","doi-asserted-by":"publisher","first-page":"110255","DOI":"10.1016\/j.clim.2024.110255","volume":"264","author":"M Tada","year":"2024","unstructured":"Tada, M. et al. Itaconate reduces proliferation and migration of fibroblast-like synoviocytes and ameliorates arthritis models. Clin. Immunol. 264, 110255 (2024).","journal-title":"Clin. Immunol."},{"key":"1323_CR151","doi-asserted-by":"publisher","first-page":"w20187","DOI":"10.4414\/smw.2020.20187","volume":"150","author":"J Intemann","year":"2020","unstructured":"Intemann, J., Gorter, D. J. J. D., Naylor, A. J., Dankbar, B. & Wehmeyer, C. Importance of osteocyte-mediated regulation of bone remodelling in inflammatory bone disease. Swiss Med. Wkly 150, w20187 (2020).","journal-title":"Swiss Med. Wkly"},{"key":"1323_CR152","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3325\/cmj.2016.57.89","volume":"57","author":"K Malysheva","year":"2016","unstructured":"Malysheva, K. et al. Interleukin 6\/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. Croat. Med. J. 57, 89\u201398 (2016).","journal-title":"Croat. Med. J."},{"key":"1323_CR153","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156\u2013163 (2007).","journal-title":"Nat. Med."},{"key":"1323_CR154","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass","year":"2005","unstructured":"Glass, D. A. et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751\u2013764 (2005).","journal-title":"Dev. Cell"},{"key":"1323_CR155","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/s10067-021-05766-9","volume":"40","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Dickkopf-1 perpetuated synovial fibroblast activation and synovial angiogenesis in rheumatoid arthritis. Clin. Rheumatol. 40, 4279\u20134288 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1323_CR156","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jbmr.1488","volume":"27","author":"M Rauner","year":"2011","unstructured":"Rauner, M. et al. WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J. Bone Miner. Res. 27, 575\u2013585 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR157","doi-asserted-by":"publisher","unstructured":"Mueller, A. A. et al. Wnt signaling drives stromal inflammation in inflammatory arthritis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.06.631510 (2025).","DOI":"10.1101\/2025.01.06.631510"},{"key":"1323_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099053","volume":"9","author":"R Menghini","year":"2014","unstructured":"Menghini, R. et al. Toll-Like receptor 4 mediates endothelial cell activation through NF-\u03baB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis. PLoS One 9, e99053 (2014).","journal-title":"PLoS One"},{"key":"1323_CR159","first-page":"120328","volume":"2010","author":"JDvan Buul","year":"2010","unstructured":"Buul, J. D. van et al. ICAM-1 clustering on endothelial cells recruits VCAM-1. BioMed. Res. Int. 2010, 120328 (2010).","journal-title":"BioMed. Res. Int."},{"key":"1323_CR160","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","volume":"152","author":"AE Koch","year":"1994","unstructured":"Koch, A. E. et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149\u20134156 (1994).","journal-title":"J. Immunol."},{"key":"1323_CR161","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2","volume":"44","author":"S Ballara","year":"2001","unstructured":"Ballara, S. et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44, 2055\u20132064 (2001).","journal-title":"Arthritis Rheum."},{"key":"1323_CR162","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/keh524","volume":"44","author":"PC Taylor","year":"2005","unstructured":"Taylor, P. C. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology 44, 721\u2013728 (2005).","journal-title":"Rheumatology"},{"key":"1323_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124909","volume":"10","author":"H-R Kim","year":"2015","unstructured":"Kim, H.-R., Kim, K.-W., Kim, B.-M., Cho, M.-L. & Lee, S.-H. The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS One 10, e0124909 (2015).","journal-title":"PLoS One"},{"key":"1323_CR164","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/art.34341","volume":"64","author":"C Wang","year":"2012","unstructured":"Wang, C. et al. CD147 induces angiogenesis through a vascular endothelial growth factor and hypoxia-inducible transcription factor 1\u03b1-mediated pathway in rheumatoid arthritis. Arthritis Rheum. 64, 1818\u20131827 (2012).","journal-title":"Arthritis Rheum."},{"key":"1323_CR165","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1189\/jlb.1205718","volume":"80","author":"SI Zittermann","year":"2006","unstructured":"Zittermann, S. I. & Issekutz, A. C. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J. Leukoc. Biol. 80, 247\u2013257 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"1323_CR166","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.3780127","volume":"80","author":"J Miotla","year":"2000","unstructured":"Miotla, J., Maciewicz, R., Kendrew, J., Feldmann, M. & Paleolog, E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Investig. 80, 1195\u20131205 (2000).","journal-title":"Lab. Investig."},{"key":"1323_CR167","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","volume":"19","author":"SK Wculek","year":"2022","unstructured":"Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A. & Sancho, D. Metabolism of tissue macrophages in homeostasis and pathology. Cell. Mol. Immunol. 19, 384\u2013408 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"1323_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77892-4","volume":"10","author":"J Taubmann","year":"2020","unstructured":"Taubmann, J. et al. Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis. Sci. Rep. 10, 21020 (2020).","journal-title":"Sci. Rep."},{"key":"1323_CR169","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174293","volume":"8","author":"C Song","year":"2023","unstructured":"Song, C. et al. Sexual dimorphism of osteoclast reliance on mitochondrial oxidation of energy substrates in the mouse. JCI Insight 8, e174293 (2023).","journal-title":"JCI Insight"},{"key":"1323_CR170","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/jbmr.1976","volume":"28","author":"Y Indo","year":"2013","unstructured":"Indo, Y. et al. Metabolic regulation of osteoclast differentiation and function. J. Bone Miner. Res. 28, 2392\u20132399 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR171","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s11914-023-00825-3","volume":"21","author":"MG Ledesma-Colunga","year":"2023","unstructured":"Ledesma-Colunga, M. G., Passin, V., Lademann, F., Hofbauer, L. C. & Rauner, M. Novel insights into osteoclast energy metabolism. Curr. Osteoporos. Rep. 21, 660\u2013669 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1323_CR172","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41420-023-01729-y","volume":"9","author":"S Arisumi","year":"2023","unstructured":"Arisumi, S. et al. Metallothionein 3 promotes osteoclast differentiation and survival by regulating the intracellular Zn2+ concentration and NRF2 pathway. Cell Death Discov. 9, 436 (2023).","journal-title":"Cell Death Discov."},{"key":"1323_CR173","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2004.07.035","volume":"301","author":"H Ha","year":"2004","unstructured":"Ha, H. et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res. 301, 119\u2013127 (2004).","journal-title":"Exp. Cell Res."},{"key":"1323_CR174","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148548","volume":"132","author":"CG Peace","year":"2022","unstructured":"Peace, C. G. & O\u2019Neill, L. A. J. The role of itaconate in host defense and inflammation. J. Clin. Investig. 132, e148548 (2022).","journal-title":"J. Clin. Investig."},{"key":"1323_CR175","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cmet.2016.06.004","volume":"24","author":"V Lampropoulou","year":"2016","unstructured":"Lampropoulou, V. et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 24, 158\u2013166 (2016).","journal-title":"Cell Metab."},{"key":"1323_CR176","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224774","volume":"83","author":"K Kachler","year":"2024","unstructured":"Kachler, K. et al. Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis. Ann. Rheum. Dis. 83, e224774 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR177","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1002\/jcp.24048","volume":"227","author":"T Takarada","year":"2012","unstructured":"Takarada, T. et al. Osteoclastogenesis is negatively regulated by D-serine produced by osteoblasts. J. Cell. Physiol. 227, 3477\u20133487 (2012).","journal-title":"J. Cell. Physiol."},{"key":"1323_CR178","doi-asserted-by":"publisher","first-page":"145362","DOI":"10.1016\/j.gene.2020.145362","volume":"771","author":"IY Karkache","year":"2021","unstructured":"Karkache, I. Y., Damodaran, J. R., Molstad, D. H. H. & Bradley, E. W. Serine\/threonine phosphatases in osteoclastogenesis and bone resorption. Gene 771, 145362 (2021).","journal-title":"Gene"},{"key":"1323_CR179","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s42255-023-00948-y","volume":"6","author":"S Stegen","year":"2024","unstructured":"Stegen, S., Moermans, K., Stockmans, I., Thienpont, B. & Carmeliet, G. The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression. Nat. Metab. 6, 141\u2013152 (2024).","journal-title":"Nat. Metab."},{"key":"1323_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14285-1","volume":"11","author":"JS Brunner","year":"2020","unstructured":"Brunner, J. S. et al. Environmental arginine controls multinuclear giant cell metabolism and formation. Nat. Commun. 11, 431 (2020).","journal-title":"Nat. Commun."},{"key":"1323_CR181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147072","volume":"131","author":"H Liu","year":"2021","unstructured":"Liu, H. & Rosen, C. J. Nitric oxide and bone: the phoenix rises again. J. Clin. Investig. 131, e147072 (2021).","journal-title":"J. Clin. Investig."},{"key":"1323_CR182","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5312\/wjo.v6.i1.106","volume":"6","author":"G Kilic","year":"2015","unstructured":"Kilic, G. & Ozgocmen, S. Hand bone mass in rheumatoid arthritis: a review of the literature. World J. Orthop. 6, 106\u2013116 (2015).","journal-title":"World J. Orthop."},{"key":"1323_CR183","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3899\/jrheum.160647","volume":"43","author":"S Nagaraj","year":"2016","unstructured":"Nagaraj, S., Finzel, S., Stok, K. S., Barnabe, C. & SPECTRA Collaboration. High-resolution Peripheral quantitative computed tomography imaging in the assessment of periarticular bone of metacarpophalangeal and wrist joints. J. Rheumatol. 43, 1921\u20131934 (2016).","journal-title":"J. Rheumatol."},{"key":"1323_CR184","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer, A. et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann. Rheum. Dis. 73, 854 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR185","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/ar3259","volume":"13","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic, M. C. et al. Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis. Arthritis Res. Ther. 13, R31 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR186","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515\u20131526 (2010).","journal-title":"Arthritis Care Res."},{"key":"1323_CR187","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch, M., Youket, T. E. & Cohen, S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323\u2013328 (2004).","journal-title":"Osteoporos. Int."},{"key":"1323_CR188","doi-asserted-by":"publisher","first-page":"105952","DOI":"10.1016\/j.jsbmb.2021.105952","volume":"213","author":"R Motavalli","year":"2021","unstructured":"Motavalli, R. et al. The clinical significance of the glucocorticoid receptors: genetics and epigenetics. J. Steroid Biochem. Mol. Biol. 213, 105952 (2021).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1323_CR189","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer, L. C. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis1. Endocrinology 140, 4382\u20134389 (1999). This article shows that glucocorticoids induce RANKL and thus osteoclastogenesis.","journal-title":"Endocrinology"},{"key":"1323_CR190","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/jbmr.1688","volume":"27","author":"S Thiele","year":"2012","unstructured":"Thiele, S. et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J. Bone Miner. Res. 27, 2242\u20132250 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR191","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/en.2003-0990","volume":"145","author":"CA O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, C. A. et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835\u20131841 (2004).","journal-title":"Endocrinology"},{"key":"1323_CR192","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","volume":"11","author":"A Rauch","year":"2010","unstructured":"Rauch, A. et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517\u2013531 (2010).","journal-title":"Cell Metab."},{"key":"1323_CR193","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jbmr.3702","volume":"34","author":"J Colditz","year":"2019","unstructured":"Colditz, J. et al. Osteogenic Dkk1 mediates glucocorticoid-induced but not arthritis-induced bone loss. J. Bone Miner. Res. 34, 1314\u20131323 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR194","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato, A. Y. et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/Sclerostin. J. Bone Miner. Res. 31, 1791\u20131802 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR195","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s00774-015-0702-2","volume":"34","author":"H Kanagawa","year":"2016","unstructured":"Kanagawa, H. et al. Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J. Bone Miner. Metab. 34, 526\u2013531 (2016).","journal-title":"J. Bone Miner. Metab."},{"key":"1323_CR196","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1186\/ar4398","volume":"15","author":"S Revu","year":"2013","unstructured":"Revu, S., Nereg\u00e5rd, P., Klint, E., Korotkova, M. & Catrina, A. I. Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res. Ther. 15, R205 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR197","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13075-015-0760-9","volume":"17","author":"AH Hensvold","year":"2015","unstructured":"Hensvold, A. H. et al. Serum RANKL levels associate with anti-citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res. Ther. 17, 239 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR198","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bone.2008.09.014","volume":"44","author":"C Fan","year":"2009","unstructured":"Fan, C. et al. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 44, 61\u201370 (2009).","journal-title":"Bone"},{"key":"1323_CR199","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.1780370208","volume":"37","author":"KP May","year":"1994","unstructured":"May, K. P., West, S. G., Mcdermott, M. T. & Huffer, W. E. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum. 37, 201\u2013206 (1994).","journal-title":"Arthritis Rheum."},{"key":"1323_CR200","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/art.1780390317","volume":"39","author":"KP May","year":"1996","unstructured":"May, K. P., Mercill, D., McDermott, M. T. & West, S. G. The effect of methotrexate on mouse bone cells in culture. Arthritis Rheum. 39, 489\u2013494 (1996).","journal-title":"Arthritis Rheum."},{"key":"1323_CR201","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/8756-3282(94)00032-U","volume":"16","author":"DL Wheeler","year":"1995","unstructured":"Wheeler, D. L. et al. The short- and long-term effects of methotrexate on the rat skeleton. Bone 16, 215\u2013221 (1995).","journal-title":"Bone"},{"key":"1323_CR202","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.bone.2007.07.021","volume":"41","author":"CJ Xian","year":"2007","unstructured":"Xian, C. J. et al. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 41, 842\u2013850 (2007).","journal-title":"Bone"},{"key":"1323_CR203","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003919","volume":"10","author":"I Tronstad","year":"2024","unstructured":"Tronstad, I. et al. Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway. RMD Open 10, e003919 (2024).","journal-title":"RMD Open"},{"key":"1323_CR204","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","volume":"41","author":"NJ Minaur","year":"2002","unstructured":"Minaur, N. J. et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 41, 741\u2013749 (2002).","journal-title":"Rheumatology"},{"key":"1323_CR205","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00223-020-00765-5","volume":"108","author":"T Rolvien","year":"2021","unstructured":"Rolvien, T. et al. Clinical and radiological characterization of patients with immobilizing and progressive stress fractures in methotrexate osteopathy. Calcif. Tissue Int. 108, 219\u2013230 (2021).","journal-title":"Calcif. Tissue Int."},{"key":"1323_CR206","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00198-020-05664-x","volume":"32","author":"F Robin","year":"2021","unstructured":"Robin, F. et al. Methotrexate osteopathy: five cases and systematic literature review. Osteoporos. Int. 32, 225\u2013232 (2021).","journal-title":"Osteoporos. Int."},{"key":"1323_CR207","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00223-024-01290-5","volume":"115","author":"FN Brackel","year":"2024","unstructured":"Brackel, F. N., von, Grambeck, J., Barvencik, F., Amling, M. & Oheim, R. MTX osteopathy versus osteoporosis including response to treatment data \u2014 a retrospective single center study including 172 patients. Calcif. Tissue Int. 115, 599\u2013610 (2024).","journal-title":"Calcif. Tissue Int."},{"key":"1323_CR208","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1002\/art.20637","volume":"50","author":"C Lee","year":"2004","unstructured":"Lee, C. et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor \u03baB, osteoprotegerin, and receptor activator of nuclear factor \u03baB ligand. Arthritis Rheum. 50, 3831\u20133843 (2004).","journal-title":"Arthritis Rheum."},{"key":"1323_CR209","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/s10165-006-0531-1","volume":"17","author":"A Suematsu","year":"2007","unstructured":"Suematsu, A. et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod. Rheumatol. 17, 17\u201323 (2007).","journal-title":"Mod. Rheumatol."},{"key":"1323_CR210","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00774-003-0489-4","volume":"22","author":"Y Kobayashi","year":"2004","unstructured":"Kobayashi, Y. et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J. Bone Miner. Metab. 22, 318\u2013328 (2004).","journal-title":"J. Bone Miner. Metab."},{"key":"1323_CR211","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5455\/medarh.2016.70.101-103","volume":"70","author":"S Rexhepi","year":"2016","unstructured":"Rexhepi, S., Rexhepi, M., Sahat\u00e7iu-Meka, V., Mahmutaj, V. & Boshnjaku, S. The impact of low-dose disease-modifying anti-rheumatics drugs (DMARDs) on bone mineral density of premenopausal women in early rheumatoid arthritis. Med. Arch. 70, 101 (2016).","journal-title":"Med. Arch."},{"key":"1323_CR212","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00296-008-0682-9","volume":"29","author":"A Pfeil","year":"2009","unstructured":"Pfeil, A. et al. Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. Rheumatol. Int. 29, 287\u2013295 (2009).","journal-title":"Rheumatol. Int."},{"key":"1323_CR213","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett, G., Elewaut, D., McInnes, I. B., Dayer, J.-M. & Neurath, M. F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19, 822\u2013824 (2013).","journal-title":"Nat. Med."},{"key":"1323_CR214","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/ar2219","volume":"9","author":"H Marotte","year":"2007","unstructured":"Marotte, H. et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res. Ther. 9, R61 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"1323_CR215","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis, M. et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF\u03baB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1495 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR216","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange, U., Teichmann, J., M\u00fcller-Ladner, U. & Strunk, J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-\u03b1 antibody: a prospective open-label pilot study. Rheumatology 44, 1546\u20131548 (2005). This article shows that anti-TNF therapy is osteoprotective in arthritis.","journal-title":"Rheumatology"},{"key":"1323_CR217","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2008.091611","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts, C. A. et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann. Rheum. Dis. 68, 373 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR218","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","volume":"52","author":"CLM Krieckaert","year":"2013","unstructured":"Krieckaert, C. L. M., Nurmohamed, M. T., Wolbink, G. & Lems, W. F. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology 52, 547\u2013553 (2013).","journal-title":"Rheumatology"},{"key":"1323_CR219","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/ard.2007.076604","volume":"67","author":"F Chopin","year":"2008","unstructured":"Chopin, F. et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann. Rheum. Dis. 67, 353\u2013357 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR220","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/ard.2009.127787","volume":"70","author":"DA Eekman","year":"2011","unstructured":"Eekman, D. A. et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 389 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-54","volume":"12","author":"M Hoff","year":"2011","unstructured":"Hoff, M. et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet. Disord. 12, 54 (2011).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1323_CR222","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard.2010.148395","volume":"70","author":"S Finzel","year":"2011","unstructured":"Finzel, S. et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann. Rheum. Dis. 70, 1587 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR223","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/ard.2009.119156","volume":"69","author":"C Lukas","year":"2010","unstructured":"Lukas, C., Heijde, D., van der, Fatenajad, S. & Landew\u00e9, R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann. Rheum. Dis. 69, 851 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR224","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","volume":"35","author":"N Saidenberg-Kermanac\u2019h","year":"2004","unstructured":"Saidenberg-Kermanac\u2019h, N. et al. TNF-\u03b1 antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35, 1200\u20131207 (2004).","journal-title":"Bone"},{"key":"1323_CR225","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.amjmed.2022.01.017","volume":"135","author":"S Abtahi","year":"2022","unstructured":"Abtahi, S. et al. Biological disease-modifying antirheumatic drugs and osteoporotic fracture risk in patients with rheumatoid arthritis: a Danish cohort study. Am. J. Med. 135, 879\u2013888.e3 (2022).","journal-title":"Am. J. Med."},{"key":"1323_CR226","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jbmr.1489","volume":"27","author":"SY Kim","year":"2012","unstructured":"Kim, S. Y., Schneeweiss, S., Liu, J. & Solomon, D. H. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J. Bone Miner. Res. 27, 789\u2013796 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR227","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/acr.21937","volume":"65","author":"VK Kawai","year":"2013","unstructured":"Kawai, V. K. et al. Initiation of tumor necrosis factor \u03b1 antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res. 65, 1085\u20131094 (2013).","journal-title":"Arthritis Care Res."},{"key":"1323_CR228","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","volume":"15","author":"KA Coulson","year":"2009","unstructured":"Coulson, K. A., Reed, G., Gilliam, B. E., Kremer, J. M. & Pepmueller, P. H. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J. Clin. Rheumatol. 15, 155\u2013160 (2009).","journal-title":"J. Clin. Rheumatol."},{"key":"1323_CR229","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","volume":"78","author":"G Ozen","year":"2019","unstructured":"Ozen, G., Pedro, S., Wolfe, F. & Michaud, K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 78, 1041\u20131047 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR230","first-page":"3416","volume":"25","author":"F Shao","year":"2021","unstructured":"Shao, F., Li, H.-C., Wang, M.-J. & Cui, C.-M. Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 25, 3416\u20133424 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"1323_CR231","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini, R. N. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817\u20132829 (2006).","journal-title":"Arthritis Rheum."},{"key":"1323_CR232","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987\u2013997 (2008).","journal-title":"Lancet"},{"key":"1323_CR233","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/art.21537","volume":"54","author":"PKK Wong","year":"2006","unstructured":"Wong, P. K. K. et al. Interleukin-6 modulates production of T lymphocyte\u2013derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158\u2013168 (2006).","journal-title":"Arthritis Rheum."},{"key":"1323_CR234","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2018-214894","volume":"78","author":"S Finzel","year":"2019","unstructured":"Finzel, S. et al. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann. Rheum. Dis. 78, 1186\u20131191 (2019). This article investigates the effect of cytokine-blockers on bone erosions using high-resolution peripheral quantitative computed tomography.","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR235","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR236","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63, 609\u2013621 (2011).","journal-title":"Arthritis Rheum."},{"key":"1323_CR237","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero, P., Thompson, E., Woodworth, T. & Smolen, J. S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 62, 33\u201343 (2010).","journal-title":"Arthritis Rheum."},{"key":"1323_CR238","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal, M. A. et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE Study (NCT00106522). Semin. Arthritis Rheum. 42, 131\u2013139 (2012).","journal-title":"Semin. Arthritis Rheum."},{"key":"1323_CR239","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/art.24781","volume":"60","author":"R Axmann","year":"2009","unstructured":"Axmann, R. et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 60, 2747\u20132756 (2009).","journal-title":"Arthritis Rheum."},{"key":"1323_CR240","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.yexmp.2008.03.003","volume":"84","author":"A Kato","year":"2008","unstructured":"Kato, A. et al. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp. Mol. Pathol. 84, 262\u2013270 (2008).","journal-title":"Exp. Mol. Pathol."},{"key":"1323_CR241","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5114\/reum.2022.120756","volume":"60","author":"SGA Khayyat","year":"2022","unstructured":"Khayyat, S. G. A. et al. Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study. Reumatologia 60, 326\u2013331 (2022).","journal-title":"Reumatologia"},{"key":"1323_CR242","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","volume":"53","author":"K Kume","year":"2014","unstructured":"Kume, K. et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology 53, 900\u2013903 (2014).","journal-title":"Rheumatology"},{"key":"1323_CR243","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot, K. et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Jt Bone Spine 82, 109\u2013115 (2015).","journal-title":"Jt Bone Spine"},{"key":"1323_CR244","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67, 1603 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR245","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/annrheumdis-2015-eular.2214","volume":"74","author":"M Tada","year":"2015","unstructured":"Tada, M. et al. FRI0062 Influence of biologic agents on bone mineral density and bone mineral markers in patients with rheumatoid arthritis: data from the airtight study. Ann. Rheum. Dis. 74, 441\u2013442 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR246","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer, J. M. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144, 865\u2013876 (2006).","journal-title":"Ann. Intern. Med."},{"key":"1323_CR247","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77392-9","volume":"14","author":"N Iwamoto","year":"2024","unstructured":"Iwamoto, N. et al. Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT. Sci. Rep. 14, 27673 (2024).","journal-title":"Sci. Rep."},{"key":"1323_CR248","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00296-010-1560-9","volume":"31","author":"G Hein","year":"2011","unstructured":"Hein, G. et al. Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol. Int. 31, 269\u2013272 (2011).","journal-title":"Rheumatol. Int."},{"key":"1323_CR249","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2011-200198","volume":"71","author":"MJH Boumans","year":"2012","unstructured":"Boumans, M. J. H. et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann. Rheum. Dis. 71, 108 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR250","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5114\/reum.2021.108430","volume":"59","author":"SGA Khayyat","year":"2021","unstructured":"Khayyat, S. G. A. et al. Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis \u2013 retrospective study. Reumatologia 59, 206\u2013210 (2021).","journal-title":"Reumatologia"},{"key":"1323_CR251","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/eci.12.19","volume":"8","author":"CA Zerbini","year":"2012","unstructured":"Zerbini, C. A. & Lomonte, A. B. V. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 8, 319\u2013331 (2012).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1323_CR252","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan, P. G. et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann. Rheum. Dis. 75, 1024 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR253","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377\u20132386 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR254","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer, J. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 159, 253\u2013261 (2013).","journal-title":"Ann. Intern. Med."},{"key":"1323_CR255","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/art.34649","volume":"64","author":"TP LaBranche","year":"2012","unstructured":"LaBranche, T. P. et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 64, 3531\u20133542 (2012).","journal-title":"Arthritis Rheum."},{"key":"1323_CR256","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","volume":"32","author":"A Hamar","year":"2021","unstructured":"Hamar, A. et al. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos. Int. 32, 1621\u20131629 (2021).","journal-title":"Osteoporos. Int."},{"key":"1323_CR257","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221142346","volume":"14","author":"KE Hansen","year":"2022","unstructured":"Hansen, K. E. et al. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 14, 1759720\u00d7221142346 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1323_CR258","doi-asserted-by":"publisher","first-page":"116654","DOI":"10.1016\/j.bone.2022.116654","volume":"168","author":"C G\u00f3mez-Vaquero","year":"2023","unstructured":"G\u00f3mez-Vaquero, C. et al. High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study. Bone 168, 116654 (2023).","journal-title":"Bone"},{"key":"1323_CR259","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14397595.2020.1812835","volume":"31","author":"Y Fujieda","year":"2020","unstructured":"Fujieda, Y. et al. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): a multicentre, double-blind, randomized, placebo-controlled trial. Mod. Rheumatol. 31, 593\u2013599 (2020).","journal-title":"Mod. Rheumatol."},{"key":"1323_CR260","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00198-018-4494-9","volume":"29","author":"K Kumagai","year":"2018","unstructured":"Kumagai, K. et al. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison. Osteoporos. Int. 29, 1637\u20131642 (2018).","journal-title":"Osteoporos. Int."},{"key":"1323_CR261","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.1780390307","volume":"39","author":"F Eggelmeijer","year":"1996","unstructured":"Eggelmeijer, F. et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39, 396\u2013402 (1996).","journal-title":"Arthritis Rheum."},{"key":"1323_CR262","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","volume":"17","author":"WF Lems","year":"2006","unstructured":"Lems, W. F. et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos. Int. 17, 716\u2013723 (2006).","journal-title":"Osteoporos. Int."},{"key":"1323_CR263","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1002\/art.23988","volume":"58","author":"T Mawatari","year":"2008","unstructured":"Mawatari, T. et al. Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum. 58, 3340\u20133349 (2008).","journal-title":"Arthritis Rheum."},{"key":"1323_CR264","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00044011-200828030-00002","volume":"28","author":"K Katayama","year":"2008","unstructured":"Katayama, K. & Matsuno, T. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy. Clin. Drug Investig. 28, 149\u2013158 (2008).","journal-title":"Clin. Drug Investig."},{"key":"1323_CR265","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/art.21824","volume":"54","author":"SJ Jarrett","year":"2006","unstructured":"Jarrett, S. J. et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 54, 1410\u20131414 (2006).","journal-title":"Arthritis Rheum."},{"key":"1323_CR266","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s13018-019-1492-3","volume":"14","author":"J Xie","year":"2019","unstructured":"Xie, J. et al. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. J. Orthop. Surg. Res. 14, 421 (2019).","journal-title":"J. Orthop. Surg. Res."},{"key":"1323_CR267","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/jbmr.5650101115","volume":"10","author":"P Sansoni","year":"1995","unstructured":"Sansoni, P. et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J. Bone Miner. Res. 10, 1719\u20131725 (1995).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR268","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1359\/jbmr.071031","volume":"23","author":"P D\u2019Amelio","year":"2009","unstructured":"D\u2019Amelio, P. et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res. 23, 373\u2013379 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"1323_CR269","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/acr.20172","volume":"62","author":"JT Sharp","year":"2010","unstructured":"Sharp, J. T. et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res. 62, 537\u2013544 (2010).","journal-title":"Arthritis Care Res."},{"key":"1323_CR270","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/acr.20004","volume":"62","author":"A Deodhar","year":"2010","unstructured":"Deodhar, A. et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res. 62, 569\u2013574 (2010).","journal-title":"Arthritis Care Res."},{"key":"1323_CR271","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore, R. K. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872\u2013875 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR272","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"Ferrari-Lacraz, S. & Ferrari, S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22, 435\u2013446 (2011).","journal-title":"Osteoporos. Int."},{"key":"1323_CR273","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/art.39075","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis, J. R. et al. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 67, 1456\u20131464 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1323_CR274","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi, T. et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann. Rheum. Dis. 78, 899\u2013907 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1323_CR275","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434\u20131441 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR276","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"BL Langdahl","year":"2018","unstructured":"Langdahl, B. L. et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 116, 58\u201366 (2018).","journal-title":"Bone"},{"key":"1323_CR277","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00774-017-0861-4","volume":"36","author":"K Ebina","year":"2018","unstructured":"Ebina, K. et al. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J. Bone Miner. Metab. 36, 478\u2013487 (2018).","journal-title":"J. Bone Miner. Metab."},{"key":"1323_CR278","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/art.40156","volume":"69","author":"DH Solomon","year":"2017","unstructured":"Solomon, D. H. et al. Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 69, 1741\u20131750 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1323_CR279","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajhp\/zxy022","volume":"76","author":"A Sleeman","year":"2019","unstructured":"Sleeman, A. & Clements, J. N. Abaloparatide: a new pharmacological option for osteoporosis. Am. J. Health Syst. Pharm. 76, 130\u2013135 (2019).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"1323_CR280","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412\u2013420 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR281","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417\u20131427 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR282","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","volume":"35","author":"K Ebina","year":"2024","unstructured":"Ebina, K. et al. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case\u2013control study. Osteoporos. Int. 35, 841\u2013849 (2024).","journal-title":"Osteoporos. Int."},{"key":"1323_CR283","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa, T. et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod. Rheumatol. 33, 96\u2013103 (2022).","journal-title":"Mod. Rheumatol."},{"key":"1323_CR284","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/mr\/roac059","volume":"33","author":"T Mochizuki","year":"2022","unstructured":"Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R. & Okazaki, K. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod. Rheumatol. 33, 490\u2013495 (2022).","journal-title":"Mod. Rheumatol."},{"key":"1323_CR285","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/joim.20017","volume":"296","author":"CC Mok","year":"2024","unstructured":"Mok, C. C. et al. Romosozumab versus denosumab in long-term users of glucocorticoids: a pilot randomized controlled trial. J. Intern. Med. 296, 481\u2013494 (2024).","journal-title":"J. Intern. Med."},{"key":"1323_CR286","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr2.11517","volume":"5","author":"D Gordon","year":"2023","unstructured":"Gordon, D. et al. Selective inhibition of the MK2 pathway: data from a phase IIa randomized clinical trial in rheumatoid arthritis. ACR Open Rheumatol. 5, 63\u201370 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"1323_CR287","doi-asserted-by":"publisher","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","volume":"8","author":"C Wehmeyer","year":"2016","unstructured":"Wehmeyer, C. et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci. Transl. Med. 8, 330ra35 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1323_CR288","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.240","volume":"10","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. A selected small molecule prevents inflammatory osteolysis through restraining osteoclastogenesis by modulating PTEN activity. Clin. Transl. Med. 10, e240 (2020).","journal-title":"Clin. Transl. Med."},{"key":"1323_CR289","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2022.08.012","volume":"190","author":"G Manda","year":"2022","unstructured":"Manda, G. et al. Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis. Free Radic. Biol. Med. 190, 179\u2013201 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"1323_CR290","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","volume":"4","author":"J Chery","year":"2016","unstructured":"Chery, J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 4, 35\u201350 (2016).","journal-title":"Postdoc J."},{"key":"1323_CR291","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41590-019-0526-7","volume":"20","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa, T. et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat. Immunol. 20, 1631\u20131643 (2019). This article describes the occurrence of arthritis-associated osteoclast precursors in mice.","journal-title":"Nat. Immunol."},{"key":"1323_CR292","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/jcmm.13367","volume":"22","author":"Y Yamaguchi","year":"2018","unstructured":"Yamaguchi, Y. et al. Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation. J. Cell. Mol. Med. 22, 1138\u20131147 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"1323_CR293","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/ard-2022-223626","volume":"83","author":"S Cao","year":"2024","unstructured":"Cao, S. et al. L-arginine metabolism inhibits arthritis and inflammatory bone loss. Ann. Rheum. Dis. 83, 72\u201387 (2024).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01323-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:01:48Z","timestamp":1766365308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01323-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":293,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01323-9","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"22 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. declares receiving honoraria for lectures at conferences (Alexion and UCB) and advisory boards (Vifor Pharma). A.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}